Recently published results from Know Your Tumor demonstrate the feasibility and utility of a comprehensive precision medicine program to both discover actionable findings and improve progression-free survival.
ASCO updates recommendations of second-line therapy for patients with metastatic pancreatic cancer.
Adjunctive therapy appears to benefit only pancreatic head tumors and not body and tail tumors after surgical resection.
Larotrectinib produced an astounding response in a patient population with few options for continued treatment.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A national team led by a Cleveland Clinic oncologist is starting a study that involves administering aggressive multi-agent chemotherapy prior to surgery for patients with resectable pancreatic adenocarcinoma
Researchers in an ongoing trial are investigating whether preoperative chemotherapy for resectable pancreatic ductal adenocarcinoma can offer better outcomes than the current approach.
Cleveland Clinic researchers find that baseline clinical data can identify patients with resectable pancreatic cancer who are at increased risk of early mortality. The results may lead to more individualized care and improved outcomes.
Biliary cancers’ rarity, their often advanced stage at diagnosis and the scarcity of tissue biorepositories complicates treatment. Cleveland Clinic’s research and targeted treatment program aims to overcome these obstacles.
Research investigating the impact of tumor sequencing on treatment decisions in metastatic colorectal cancer patients finds genomic profiling enhances therapeutic options.
Early Cleveland Clinic findings show that expanded cancer genomic testing can be done quickly and often identifies potential therapeutic targets. Clinical trials are evaluating compounds specifically aimed at those targets.